Skip to main content
Premium Trial:

Request an Annual Quote

Miraculins Raises $505K in Private Placement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Miraculins has completed a private placement of 10.2 million units, raising C$510,000 (US$505,000) in proceeds.

The Winnipeg, Canada-based diagnostics firm said that it has sold the units at C$.05 each. The units are comprised of one common share and one share purchase warrant. Each warrant entitles the holder to purchase one share at a price of C$.10 for a period of 12 months after the warrant is issued.

Miraculins noted that the warrants are callable, at its option, in the event the shares trade at or above $.14 per share for any 20 out of 30 consecutive trading days.

Miraculins, which makes biomarker-based diagnostic tests, said that it will use the proceeds for R&D and working capital purposes.

Its shares closed up 23 percent at C$.08 per share in Thursday trade on the TSX Venture Exchange.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.